Comparative evaluation of phacoemulsification combined with goniosynechi-alysis with goniotomy versus trabeculectomy in patients with angle-closure glaucoma and cataract

对闭角型青光眼合并白内障患者进行超声乳化联合房角分离术及房角切开术与单纯小梁切除术的疗效比较评价

阅读:1

Abstract

PURPOSE: This study aims to evaluate the effectiveness and safety of phacoemulsification cataract extraction with intraocular lens implantation (PEI) combined with Goniosynechialysis (GSL), Goni-otomy (GT), and PEI combined with Trabeculectomy (TRAB), in managing mid to late-stage Primary Angle-Closure Glaucoma (PACG) combined with cataract. METHODS: A retrospective analysis was conducted on 42 patients (54 eyes) with mid to late-stage PACG combined with cataracts, who were previously treated at Dongyang People's Hospital from December 3, 2020, to November 30, 2023. Among them, 16 (24 eyes) underwent PEI-GSL-GT, and 26 (30 eyes) underwent PEI-TRAB. After minimum of 6 months of postoperative follow-up, observations were made on intraocular pressure (IOP), best-corrected visual acuity (BCVA), use of antiglaucoma medications, and complications for both surgical procedures. RESULTS: Postoperative BCVA improved significantly in both groups. In the PEI-GSL-GT group, IOP decreased by 26% (from 17.75 to 13.13 mmHg); in the PEI-TRAB group, it decreased by 14.5% (from 17.87 to 15.27 mmHg). At the 6-month follow-up, IOP was significantly lower in the PEI-GSL-GT group compared to the PEI-TRAB group. The number of patients using antiglaucoma medications decreased significantly in both groups. By the 6-month follow-up, no patients in the PEI-GSL-GT group were using antiglaucoma medications. CONCLUSIONS: PEI-GSL-GT is more effective than PEI-TRAB in lowering IOP in patients with mid to late-stage PACG, potentially reducing or discontinuing postoperative antiglaucoma medications, decreasing postoperative complications, and improving visual acuity.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。